| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e5c121269689cbab9b3a4548b15caf3 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2007-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f51b1850c50cf0a1223553f6b516d6af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30a361566bd528cce19a7922a75d8338 |
| publicationDate |
2009-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2009007255-A |
| titleOfInvention |
Lung cancer drug |
| abstract |
An anticancer agent effective for lung cancer is provided. An anticancer agent comprising a substance that inhibits the binding of HB-EGF and EGF receptor by binding to HB-EGF, wherein the cancer to be treated is Gefitinib-sensitive and / or Gefitinib-resistant lung cancer An anticancer agent. [Selection] Figure 1 |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9127836-B2 |
| priorityDate |
2007-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |